Methotrexat Lederle (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a key cofactor for synthesising purines and pyrimidines. This inhibition reduces DNA, RNA and protein production, limiting the growth of rapidly dividing cells and modulating immune responses.

The prescribed dose of Methotrexat Lederle is set by the treating physician based on the specific indication, patient weight, renal and hepatic function, and any concurrent therapies. Dosage regimens vary widely, so patients should follow the prescriber’s exact instructions.

Methotrexat Lederle is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it can be excreted in milk and affect the infant.

To order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, then replies with pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Methotrexate is an antimetabolite, whereas alternatives such as biologic DMARDs (e.g., adalimumab) target specific cytokines. Methotrexate is generally less expensive and administered orally, but biologics may offer faster symptom control for some patients. Choice depends on disease severity, comorbidities, cost considerations and physician judgment.

Methotrexat Lederle tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

The medication is taken orally, usually with a full glass of water. Depending on the prescribing regimen, it may be taken once weekly or as directed by the clinician. Patients are often advised to take folic acid supplements to reduce certain side effects, but they should follow the prescriber’s guidance.

Serious risks include bone marrow suppression leading to pancytopenia, severe liver toxicity or fibrosis, pulmonary complications such as interstitial pneumonitis, and life‑threatening infections due to immunosuppression. Patients should promptly report symptoms like persistent fever, unusual bruising, jaundice, or shortness of breath.

Methotrexat Lederle is contraindicated in pregnant or breastfeeding women, patients with severe renal or hepatic impairment, and individuals with known hypersensitivity to methotrexate or any excipients. It should also be avoided in patients receiving live vaccines or those with uncontrolled infections.